CGTX
Cognition Therapeutics Inc
NASDAQ: CGTX · HEALTHCARE · BIOTECHNOLOGY
$1.26
+6.78% today
Updated 2026-04-30
Market cap
$114.37M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.32
Dividend yield
—
52W range
$0 – $4
Volume
1.2M
Cognition Therapeutics Inc (CGTX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | $81000.00 | $98000.00 | $93000.00 | $235000.00 | $252000.00 | $266000.00 | $228000.00 |
| Gross profit | $-81000.00 | $-98000.00 | $-93000.00 | $-235000.00 | $-252000.00 | $-266000.00 | $-228000.00 |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $14.38M | $12.89M | $18.57M | $30.32M | $37.20M | $41.68M | $37.19M |
| SG&A | $3.45M | $4.52M | $10.03M | $13.23M | $13.53M | $12.29M | $10.61M |
| Operating income | $-17.83M | $-17.41M | $-28.60M | $-43.55M | $-50.72M | $-53.97M | $-47.80M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-3.74M | $-5.99M | $-10.73M | $-21.13M | $-25.51M | $-33.68M | $-47.80M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-3.82M | $-6.09M | $-10.82M | $-21.37M | $-25.76M | $-33.95M | $-48.03M |
| Interest expense | $1.02M | $1.75M | $893000.00 | $28000.00 | $27000.00 | $25000.00 | $13000.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-6.95M | $-10.07M | $-11.72M | $757000.00 | $-25.79M | $-33.97M | $-23.49M |
| Net income growth (YoY) | — | -44.9% | -16.3% | +106.5% | -3506.6% | -31.7% | +30.9% |
| Profit margin | — | — | — | — | — | — | — |